Barclays initiated research coverage on Centrus Energy Corp. The bank assigned an "Equal Weight" rating. Barclays set a price target of $207.00.
Centrus historically brokered nuclear fuel. The company now progresses towards enriching uranium.
Centrus is the only U.S. company licensed to commercially produce high-assay, low-enriched uranium (HALEU). HALEU fuels many next-generation advanced reactors. This provides a competitive advantage.
Positive industry tailwinds support the initiation. These include an impending ban on Russian uranium imports. Increased power demand also contributes.